WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015. “Interleukin Genetics is advancing on its mission to prevent and more cost-effectively manage chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We have enhanced the positioning of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to